Cargando…
Topical nepafenac for prevention of post-cataract surgery macular edema in diabetic patients: patient selection and perspectives
Since its first description, the prevention of pseudophakic cystoid macular edema (PCME) continues to pose challenges for ophthalmologists. Recent evidence suggests that prophylaxis is unnecessary in patients without risk factors. Diabetes mellitus is generally considered as a risk factor for the de...
Autores principales: | Yüksel, Bora, Karti, Ömer, Kusbeci, Tuncay |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5730051/ https://www.ncbi.nlm.nih.gov/pubmed/29269999 http://dx.doi.org/10.2147/OPTH.S132810 |
Ejemplares similares
-
Real-life outcomes of intravitreal ranibizumab, aflibercept, and dexamethasone implant administrations in patients with treatment-naïve diabetic macular edema
por: Korkmaz, Anil, et al.
Publicado: (2021) -
Topical nepafenac in the treatment of diabetic macular edema
por: Callanan, David, et al.
Publicado: (2008) -
Effect of topical nepafenac in prevention of macular edema after cataract surgery in patients with non-proliferative diabetic retinopathy
por: Sarfraz, Muhammad Haroon, et al.
Publicado: (2017) -
Evaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathy
por: Singh, Rishi, et al.
Publicado: (2012) -
Factors predicting response of pseudophakic cystoid macular edema to topical steroids and nepafenac
por: Sengupta, Sabyasachi, et al.
Publicado: (2018)